ETF Building Blocks Content Hub Biotech Ready to Participate in Healthcare Bullishness By Tom LydonOctober 29, 2021
ETF Building Blocks Content Hub Drug Price Debate May Not Hinder Biotech ETFs After All By Tom LydonSeptember 16, 2021
ETF Building Blocks Content Hub Biotech Stocks Have Colds, but They Can Heal By Tom LydonSeptember 13, 2021
Innovative ETFs Content Hub Moderna Vaccine Is Granted Authorization in Australia By Max ChenAugust 9, 2021
Beyond Basic Beta Content Hub Mostly Sanguine Regulatory Outlook for Biotech, Healthcare Names By Tom LydonJuly 30, 2021
ETF Building Blocks Content Hub Will the Biotech Space Consolidate in the Back Half of the Year? By Tom LydonJuly 14, 2021
Beyond Basic Beta Content Hub Changing FDA Regulatory Environment Could Bolster Biotech, ‘BBH’ By Tom LydonJuly 1, 2021
ETF Building Blocks Content Hub Post-Pandemic Healthcare Could Feature More Biotech M&A By Tom LydonJune 10, 2021
Innovative ETFs Content Hub Will Biotech ETFs Benefit from Biogen’s New Alzheimer’s Drug? By Ian YoungJune 9, 2021
ETF Building Blocks Content Hub As Biotech Consolidation Heats up, ‘SBIO’ Could Be a Winner By Tom LydonMay 24, 2021
Equity ETF Content Hub Biotech ETFs Make Gains Tuesday, Despite the J&J Vaccine Pause By Ian YoungApril 13, 2021
Beyond Basic Beta Content Hub Biotech Shined with Vaccines. It Can Do It Again with ‘BBH’ By Ben HernandezMarch 3, 2021
Innovative ETFs Content Hub Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Beyond Basic Beta Content Hub IPOs Are Back. Get In On the Action with the BBH ETF By Ben HernandezFebruary 9, 2021
Innovative ETFs Content Hub Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
ETF Building Blocks Content Hub ALPS ‘SBIO’ ETF: Trial Progress Meets Investing Success By Tom LydonJanuary 25, 2021
